hat
Monomethyl auristatin E revizyon: MMAE, ke yo rele tou Monomethyl auristatin E, se yon sentetik antineoplastic ajan. Paske nan toksisite li yo, li pa ka itilize kòm yon dwòg tèt li; olye, li lye nan yon antikò monoklon (MAB) ki dirije li nan selil kansè yo. Nan Non Non Propriétés pou MMAE-MAB konjigezon, non an vedotin refere a MMAE plis estrikti ki lye ak antikò a. MMAE se yon dwòg ki antimitotik ki sòti nan peptides ki fèt nan marin koki-mwens mollusc Dolabella auricularia ki rele dolastatin ki montre aktivite ki pisan nan etid preclinical, tou de nan vitro ak nan vivo, kont yon seri de lenfom, lesemi ak timè solid. MMAE montre puisans ki rive jiska 200 fwa sa yo ki nan vinblastin, yon lòt dwòg antimitotik yo itilize pou Hodgkin lenfom kòm byen ke lòt kalite kansè.
eng
Monomethyl auristatin E review: MMAE, also known as Monomethyl auristatin E, is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself; instead, it is linked to a monoclonal antibody (MAB) which directs it to the cancer cells. In International Nonproprietary Names for MMAE-MAB-conjugates, the name vedotin refers to MMAE plus its linking structure to the antibody. MMAE is a potent antimitotic drug derived from peptides occurring in marine shell-less mollusc Dolabella auricularia called dolastatins which show potent activity in preclinical studies, both in vitro and in vivo, against a range of lymphomas, leukemia and solid tumors. MMAE show potency of up to 200 times that of vinblastine, another antimitotic drug used for Hodgkin lymphoma as well as other types of cancer.